Maternal serum screening for preeclampsia: Is performance enough?

Clinical Biochemistry

Volumn 43, Issue 9, 2010, Pages 707-708

  Audibert, François ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Preeclampsia; Screening

Indexed keywords

ACETYLSALICYLIC ACID; INHIBIN A; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A; VASCULOTROPIN RECEPTOR 1;

AUTOMATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DOPPLER FLOWMETRY; DOWN SYNDROME; EDITORIAL; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY; LOW DRUG DOSE; PREDICTION; PREECLAMPSIA; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

EID: 77952958327     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.03.004     Document Type: Editorial

References (21)

1. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia. Lancet 2005, 365:785-799.
2. Audibert F. Screening for pre-eclampsia: the quest for the Holy Grail?. Lancet 2005, 365:1367-1369.
3. Conde-Agudelo A., Villar J., Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004, 104:1367-1391.
4. Zhong Y., Tuuli M., Odibo A.O. First-trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction. Prenat Diagn 2010, 30(4):293-308.
5. Kusanovic J.P., Romero R., Chaiworapongsa T., et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009, 22:1021-1038.
6. Tsatsaris V., Goffin F., Foidart J. Circulating angiogenic factors and preeclampsia. New Engl J Med 2004, 350:2003.
7. Schiettecatte J, Russcher H, Anckaert E, et al. Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. Clin Biochem 2010 in press.
8. Levine R.J., Lam C., Qian C., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006, 355:992-1005.
9. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350:672-683.
10. Maynard S.E., Min J.-Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111:649-658.
11. Akolekar R., de Cruz J., Foidart J.M., Munaut C., Nicolaides K.H. Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13weeks of gestation in preeclampsia. Prenat Diagn 2010, 30:191-197.
12. Askie L.M., Duley L., Henderson-Smart D.J., Stewart L.A. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007, 369:1791-1798.
13. Bujold E., Morency A.M., Roberge S., Lacasse Y., Forest J.C., Giguere Y. Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. J Obstet Gynaecol Can 2009, 31:818-826.
14. Akolekar R., Minekawa R., Veduta A., Romero X.C., Nicolaides K.H. Maternal plasma inhibin A at 11-13weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn 2009, 29:753-760.
15. Salomon L.J., Benattar C., Audibert F., et al. Severe preeclampsia is associated with high inhibin A levels and normal leptin levels at 7 to 13weeks into pregnancy. Am J Obstet Gynecol 2003, 189:1517-1522.
16. Smith G.C., Stenhouse E.J., Crossley J.A., Aitken D.A., Cameron A.D., Connor J.M. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab 2002, 87:1762-1767.
17. Poon L.C., Kametas N.A., Chelemen T., Leal A., Nicolaides K.H. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens 2010, 24:104-110.
18. Poon L.C., Kametas N.A., Maiz N., Akolekar R., Nicolaides K.H. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009, 53:812-818.
19. Poon L.C., Maiz N., Valencia C., Plasencia W., Nicolaides K.H. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 2009, 33:23-33.
20. Spencer K., Crossley J.A., Aitken D.A., Nix A.B., Dunstan F.D., Williams K. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome. Ann Clin Biochem 2003, 40:219-231.
21. Duckitt K., Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005, 330:565.